Literature DB >> 16046616

The effect of dipyridamole on vascular cell-derived reactive oxygen species.

Subrata Chakrabarti1, Olga Vitseva, David Iyu, Sonia Varghese, Jane E Freedman.   

Abstract

Platelet and vascular stimulation leads to release of reactive oxygen species (ROS) that are known to influence vascular reactivity and thrombosis. Dipyridamole is a vasodilator and platelet inhibitor that has previously been shown to have direct antioxidant properties. The antioxidant effects of dipyridamole on vascular cell-derived ROS are not known; therefore, dipyridamole was incubated with endothelial cells and platelets and cellular redox status and release of endogenous ROS were assessed. Dipyridamole decreased intracellular basal ROS generation from endothelial cells as measured by DCFDA (2',7'-dichlorodihydrofluorescein diacetate) oxidation. Incubation of endothelial cells with dipyridamole also attenuated t-butylhydroperoxide-induced oxidative stress. Using a redox-sensitive fluorescent dye, dipyridamole improved cellular activity after treatment with t-butylhydroperoxide. Incubation with dipyridamole did not alter platelet release of nitric oxide or hydrogen peroxide but significantly attenuated superoxide release. Using flow cytometry and confocal microscopy, dipyridamole decreased platelet ROS generation. Dipyridamole also suppressed platelet-soluble CD40 ligand release. In summary, at therapeutically relevant concentrations, dipyridamole suppresses the formation of ROS in platelets and endothelial cells and improves cellular redox status. These data suggest that the redox-dependent properties of dipyridamole have a direct effect on vascular cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046616     DOI: 10.1124/jpet.105.089987

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress.

Authors:  Christopher B Pattillo; Shyamal C Bir; Billy G Branch; Eric Greber; Xinggui Shen; Sibile Pardue; Rakesh P Patel; Christopher G Kevil
Journal:  Free Radic Biol Med       Date:  2010-11-09       Impact factor: 7.376

Review 2.  The role of the blood transcriptome in innate inflammation and stroke.

Authors:  Jane E Freedman; Olga Vitseva; Kahraman Tanriverdi
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

3.  Lactodifucotetraose, a human milk oligosaccharide, attenuates platelet function and inflammatory cytokine release.

Authors:  David S Newburg; Ayse C Tanritanir; Subrata Chakrabarti
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 4.  Translational therapeutics of dipyridamole.

Authors:  Hyung-Hwan Kim; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

5.  New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.

Authors:  Yogendra Kanthi; Jason S Knight; Yu Zuo; David J Pinsky
Journal:  JCI Insight       Date:  2020-07-23

6.  Reactive Oxygen Species Generated by CD45-Cells Distinct from Leukocyte Population in Platelet Concentrates Is Correlated with the Expression and Release of Platelet Activation Markers during Storage.

Authors:  Mehran Ghasemzadeh; Ehteramolsadat Hosseini; Amin Shahbaz Ghasabeh; Kamran Mousavi Hosseini
Journal:  Transfus Med Hemother       Date:  2018-01-03       Impact factor: 3.747

7.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

8.  Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.

Authors:  Hans Worthmann; Reinhard Dengler; Helmut Schumacher; Andreas Schwartz; Wolfgang G Eisert; Ralf Lichtinghagen; Karin Weissenborn
Journal:  Int J Mol Sci       Date:  2012-07-12       Impact factor: 6.208

9.  Proton-coupled electron-transfer mechanism for the radical scavenging activity of cardiovascular drug dipyridamole.

Authors:  Abolfazl Barzegar
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

10.  Reduction of microglial activity in a model of multiple sclerosis by dipyridamole.

Authors:  Scott Sloka; Luanne M Metz; Walter Hader; Yves Starreveld; V Wee Yong
Journal:  J Neuroinflammation       Date:  2013-07-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.